Seven Must-Read Stories (Week ending January 16, 2016)
Another chance to catch the most interesting and important articles from the previous week on MIT Technology Review.
- Illumina’s Bid to Beat Cancer with DNA Tests
The DNA sequencing giant will launch a new company, Grail, to develop blood tests to detect cancer.
- Hope in a Glove for Parkinson’s Patients
A wearable device promises to help steady hand tremors by using an old technology—gyroscopes.
- Parents Turn to Prozac to Treat Down Syndrome
The disorder known as trisomy 21 is untreatable. Or is it? Some families think an antidepressant could help.
- Big Pharma Doubles Down on CRISPR for New Drugs
A joint venture between Bayer and CRISPR Therapeutics is the latest effort to make CRISPR drugs that could target and modify cells inside the body.
- RIP David Bowie, Internet Pioneer
Long before MySpace, the late rock star was focused on connecting with his fans online.
- In Pursuit of an Affordable Tablet for the Blind
By borrowing from microfluidics, a team of University of Michigan researchers are reinventing the Braille display to be cheaper and more useful.
- Advanced Nuclear Startup Terrestrial Energy Lands Initial Funding
Canadian startup pursuing an advanced molten-salt nuclear reactor gets significant outside backing. <
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.